Anichini Gabriele, Terrosi Chiara, Alessandri Giulia, Miceli Giovanni B, Borrelli Emma, Fabrizi Simonetta, Savellini Gianni G, Cusi Maria G
Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Preventive Medicine and Health Surveillance Unit, Santa Maria delle Scotte Hospital, Siena, Italy.
J Med Virol. 2024 Dec;96(12):e70135. doi: 10.1002/jmv.70135.
Despite the availability of a highly efficacious vaccine, a global resurgence of measles infections has occurred, largely due to decreased vaccination coverage and waning immunity following the two-dose vaccination schedule. This study aims to assess the cellular immune response in individuals who did not respond to the two-dose MMR vaccine and evaluate the efficacy and durability of immune responses after booster doses. An observational study was conducted involving 24 individuals who were seronegative for measles years after completing the two-dose MMR vaccine schedule. Of these, 11 seroconverted after a single booster dose, while 13 required an additional booster. Antibody levels were monitored 1 and 3 years post-booster. Cellular immune responses were evaluated in 10 nonresponders by in vitro stimulation of PBMCs with UV-inactivated measles virus. In nonresponders, measles virus stimulation did not induce significant alterations in T, B, or NK cell populations, indicating a lack of measles-specific immune memory. However, stimulation with rubella induced a significant immune response. Booster doses in subjects with waning antibodies resulted in low IgG titers, which significantly declined over 3 years. Neutralizing antibody titers were also low for both double and single booster recipients. This study highlights the limited long-term efficacy of booster doses in individuals with waning immunity or nonresponsiveness to the measles vaccine. Current vaccination strategies relying on booster doses may not be sufficient for sustained protection in these individuals. Improving vaccine formulations to elicit stronger and longer-lasting immunity is essential for effective measles control and elimination.
尽管有高效疫苗可用,但麻疹感染在全球仍有复发,主要原因是两剂次疫苗接种计划后疫苗接种覆盖率下降和免疫力减弱。本研究旨在评估对两剂次MMR疫苗无反应个体的细胞免疫反应,并评估加强剂量后免疫反应的效力和持久性。开展了一项观察性研究,纳入24名在完成两剂次MMR疫苗接种计划数年后麻疹血清学阴性的个体。其中,11人在单次加强剂量后血清阳转,而13人需要额外一次加强剂量。在加强剂量后1年和3年监测抗体水平。通过用紫外线灭活的麻疹病毒体外刺激外周血单核细胞,对10名无反应者的细胞免疫反应进行评估。在无反应者中,麻疹病毒刺激未引起T细胞、B细胞或自然杀伤细胞群体的显著改变,表明缺乏麻疹特异性免疫记忆。然而,风疹刺激诱导了显著的免疫反应。抗体减弱的受试者接受加强剂量后IgG滴度较低,且在3年内显著下降。双次和单次加强剂量接种者的中和抗体滴度也较低。本研究强调了加强剂量对免疫力减弱或对麻疹疫苗无反应个体的长期效力有限。目前依赖加强剂量的疫苗接种策略可能不足以对这些个体提供持续保护。改进疫苗配方以引发更强和更持久的免疫力对于有效控制和消除麻疹至关重要。